compound semaglutide risks Olympia, WA Weight Loss Program (Ozempic & Wegovy) Semaglutide: Double-edged Sword with Risks

What happens next The FDA is taking public comments through June 29, 2026, before making a final decision

GSTZ1 is thought to act as a tumor suppressor in HCC due to its reported downregulation, which results in a worse prognosis for patients and increased carcinogenesis (93, 94)

Here's how they compare: Peptide Primary research area FDA status Advisory committee review BPC-157 Tissue repair, angiogenesis Not approved Yes (free base + acetate) TB-500 Actin regulation, cell migration Not approved Yes MOTS-c Mitochondrial metabolism Not approved Yes KPV Anti-inflammatory Not approved Yes GHK-Cu Copper-peptide skin/healing Not approved Not on 2026 agenda For a deeper comparison of BPC-157 and its most-researched counterpart, see our BPC-157 vs TB-500 research comparison

22 Numerous other studies too have reported similar findings of unchanged SOD activity or its protein levels in the kidneys of adult SHR

Pacifico L, Bonci E, Marandola L, Romaggioli S, Bascetta S, Chiesa C